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In patients with resectable synchronous colorectal liver metastases (CRLM), either two-
staged or simultaneous resections of the primary tumor and liver metastases are performed.
Data on radiofrequency ablation (RFA) for the treatment of CRLM during a simultaneous
procedure is lacking. The primary aim was to analyze short-term and long-term outcome of
RFA in simultaneous treatment. A secondary aim was to compare simultaneous resection
with the colorectal-first approach.
Methods
Retrospective analysis of 241 patients with colorectal cancer and synchronous CRLM
between 2000–2016. Median follow-up was 36.1 months (IQR 18.2–58.8 months). A multi-
variable analysis was performed to analyze the postoperative morbidity, using the compre-
hensive complication index. A propensity matched analysis was performed to compare
survival rates.
Results
In multivariable analysis, the best predictor of lower complication severity was treatment
with RFA (p = 0.040). Higher complication rates were encountered in patients who under-
went an abdominoperineal resection (p = 0.027) or age > 60 years (p = 0.022). The matched
analysis showed comparable overall survival in RFA treated patients versus patients under-
going a liver resection with a five year overall survival of 39.4% and 37.5%, respectively
(p = 0.782). In a second matched analysis, 5-year overall survival rates in simultaneously
treated patients (43.8%) was comparable to patients undergoing the colorectal first
approach (43.0%, p = 0.223).
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Conclusions
RFA treatment of CRLM in simultaneous procedures is associated with a lower complication
severity and non-inferior oncological outcome as compared to partial liver resection. RFA
should be considered a useful alternative to liver resection.
Introduction
About 20% of patients with colorectal cancer (CRC) already have liver metastases at the time
of presentation of their primary tumor. The most widely used intentionally curative approach
for the treatment of both tumor locations is a staged procedure with resection of the primary
tumor first, followed by liver surgery at a later stage [1]. As alternative, the liver-first staged
procedure was introduced in 2008 and was proposed to prevent progression of the liver metas-
tases during the interval between resection of the primary and the liver metastases [2,3]. The
third treatment option is to perform simultaneous surgery, in which the primary colorectal
cancer and the liver metastases are resected during the same operative session.
Simultaneous resection of the primary CRC and synchronous CRLM has been shown to be
feasible with an acceptable complication rate compared to the colorectal-first approach [4–7].
These studies score complications based on the Clavien-Dindo classification, mainly compar-
ing the incidence of major complications [8]. However, selection of only patients in a good
clinical condition contributes to this outcome. Because comorbidity and impact of surgery are
predictors for developing complications, the decision to perform two major procedures simul-
taneously or a staged procedure is important [9–11]. As an alternative for liver resection,
radiofrequency ablation (RFA) of CRLM has been shown to be associated with lower morbid-
ity and mortality and comparable survival rates [12–15].
Strikingly, in a recent multidisciplinary international consensus paper about treatment
strategy for synchronous liver metastases, RFA as a treatment option of CRLM was not even
mentioned [16]. This is due to lack of evidence, and studies in this field are certainly war-
ranted. Therefore, the aim of the present study is to analyze patients undergoing simultaneous
treatment of primary CRC and CRLM, focusing on the role of RFA in short-term complica-
tions. Furthermore, a matched analysis is performed to study survival rates in RFA-treated
patients vs. patients who underwent a liver resection. The last aim is to analyze survival rates
in matched patients who underwent a simultaneous procedure vs. colorectal-first procedure.
Patients and methods
The Department of Surgery of the University Medical Centre Groningen (UMCG) is a second-
ary and tertiary referral centre for patients with advanced colorectal cancer including CRLM
in the North-Eastern part of the Netherlands. An analysis was performed using a prospectively
maintained database of all patients with CRLM, in which for this study a selection of patients
with synchronous liver metastases was used. The procedures, performed between January
2000 and September 2016, consisted of surgery aiming at radical resection of the primary CRC
and radical resection and/or ablation of liver metastases. Only surgical resections in patients
with microscopic tumor-free margins (R0) were included in the analysis. Each patient was dis-
cussed in a tumor board of hepato-pancreato-biliary and colorectal surgeons, gastroenterolo-
gists, radiologists, radiation oncologists, pathologists and medical oncologists. Most patients
who underwent the colorectal-first procedure are treated for colorectal cancer in a primary
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hospital. Another reason for not performing simultaneous surgery is comorbidity or large liver
resections (>70% of liver volume). In simultaneous procedures, we always performed the liver
procedure first and the colorectal surgery second. The total duration of the procedure included
anesthesia induction time. A proportion of patients with rectal cancer underwent neoadjuvant
chemoradiotherapy, including 5x5 Gy radiotherapy and 6 cycles of capecitabine/oxaliplatin/
bevacizumab [17,18]. Patients with more advanced liver metastases, in whom radical liver sur-
gery was questionable, received neoadjuvant chemotherapy. They were evaluated after two or
three cycles of chemotherapy, and no further cycles were administered if the computer tomog-
raphy (CT) scan showed that a R0 resection was possible. Two or three additional cycles were
given in patients with insufficient response.
During all simultaneous procedures, intraoperative RFA was performed under ultrasound
guidance, using the RF 3000 TM Radio Frequency Ablation System (Boston Scientific, Marl-
borough, MA, USA) according to the manufacturers’ instructions. Depending on the size of
the CRLM, the 2.0, 3.5, 4.0 or 5.0 cm diameter LeVeen electrodes were inserted. Percutaneous
RFA, which was only applied in the staged approaches, was performed CT guided. In general,
RFA was contraindicated in CRLMs with a diameter> 5 cm. Ablation site recurrences were
defined as described earlier [19].
The number of CRLM and the size of the largest CRLM are based on pathological findings
of resection specimens and on CT scans in case of RFA treatment. Follow-up consisted of a
3–4 monthly survey in the first 2 years after surgery, and 6 monthly thereafter. Follow-up
consisted of serum carcinoembryonic antigen-level (CEA), liver ultrasound and thoracic X-
ray, or a multiphase contrast enhanced CT-scan or MRI scan. If equivocal results of CT/MRI
scan were obtained, positron emission tomography with [F-18]-fluorodeoxyglucose CT
(FDG-PET-CT) was performed.
Postoperative complications were scored in the first 90 days after surgery and were catego-
rized into general complications (for instance urinary tract or pulmonary complications),
bowel-related complications (anastomotic leakage, hematoma or abscess) and liver-related
complications (biloma, liver abscess). Since more than one complication can occur in the post-
operative period, we applied the comprehensive complication index (CCI) [20]. This index
integrates all complications and, on top of that, includes a grading of severity of all complica-
tions. This is especially relevant because apart from general complications (not related to the
surgical procedure itself), both the liver procedure and the colorectal procedure can have its
associated complications with variable severity.
Ethics statement
This study was approved by the local Medical Ethical committee (METc2015/343), and was
judged not to be within the scope of the Medical Research in Human Subjects Act (WMO).
In our retrospective study concerning oncological disease, it is impossible to obtain written
consent of all patients, since about 50% of patients already died of the disease at the time of
writing the manuscript.
We are, as medical doctors, bound by the law of confidentiality to keep all patient informa-
tion fully secret. This implies all authors, as researchers, are subject to this law. The local ethics
committee approved our method of including patients in our observational, retrospective
study, provided that we obey the Dutch law regulations. Because we cannot obtain patient
consent because of the aforementioned reasons, we cannot share the data because of patient
confidentiality.
The ethics committee that approved our study:
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Medical Ethical Review Board, PO Box 30.001, 9700 RB Groningen, The Netherlands,
E-mail: metc@umcg.nl.
Statistical analysis
Summary statistics are presented as percentages, median (interquartile range, IQR) or mean
(± standard deviation, SD). Non-parametrical tests (chi-square test, Mann-Whitney test and
Kruskall-Wallis H and paired equivalents) were applied when appropriate. Regression analyses
were performed to determine the risk factors for developing any complication (complication
rate) and for developing a higher comprehensive complication index (CCI) [20]. Factors with
a p-value < 0.17 in univariable analysis were entered into the multivariable model. Hazard
ratios and 95% CI are reported.
Survival rates were estimated using the Kaplan-Meier method with the stratified log-rank
test for matched comparisons. In order to compare survival, a propensity score matching was
used to reduce the influence of selection bias. A binary logistic regression was performed to
predict the probability of belonging to the RFA or non-RFA treatment group, and colorectal
first vs. simultaneous group. Covariates used for matching were location of the primary tumor,
type of colorectal surgery, major/minor liver surgery, type of liver procedure, sex, age, neoad-
juvant chemotherapy and clinical risk score [21]. We used nearest-neighbour matching, using
a 1:1 ratio, with a caliper fixed to 0.2.
In all analyses, a p-value < 0.05 was considered significant. Statistical analyses were per-
formed with IBM SPSS Statistics V22 (IBM, Armonk, New York, USA) and R software [22]
using the MatchIt package [23].
Results
Demographics
In the study period January 2000—September 2016, a total 574 patients with colorectal liver
metastases underwent 904 liver procedures, which consisted of resection, RFA or a combina-
tion of both. In the same period, 241 patients presented with synchronous liver metastases
which were treated surgically. Median follow-up of all 241 patients with synchronous liver
metastases was 36.1 months (IQR 18.2–58.8 months).
Patients who underwent a liver-first approach were excluded from further analyses due to
low number of patients (n = 15). In the remaining 226 patients, 106 underwent the simulta-
neous approach and 120 underwent the colorectal-first approach. First we analyzed the 106
patients receiving the simultaneous approach. Table 1 shows the clinicopathological character-
istics of all 106 patients in the simultaneous group. Neoadjuvant chemotherapy consisted in
88.4% (61 out of 69 patients) of the baseline treatment of capecitabine and oxaliplatin, of
which 51 patients also received bevacizumab. Major liver resections ( 3 liver segments) were
performed in 3 of the 24 patients who underwent an APR versus 25 of the 82 patients who
underwent non-APR procedures (p = 0.079).
RFA was performed in 47 patients if partial liver resection was not able to render the liver
tumor-free. More specifically, RFA was performed because of bilobar metastases (n = 28), risk
of insufficient liver function after resection (comorbidity, age or chemotherapy induced liver
parenchymal damage, n = 11) or tiny remnant metastases after neoadjuvant chemotherapy
for which resection was considered target overshoot (n = 8). The average number of ablated
lesions per patient was 1.81 (SD 1.26, range 1–7) and the average size of the largest RFA-
treated lesion was 16.4 mm (SD 9.5 mm).
The median follow-up in the patients who underwent simultaneous treatment was 25.5
(IQR = 9.43–49.53) months. At the end of the follow-up period, 47/106 (44.3%) were alive
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without recurrent disease, 26/106 (24.5%) were alive with recurrent disease and 33/106
(31.1%) patients were deceased. The in-hospital mortality was 3/106 (2.8%), all in the liver
resection group. Two out of 47 patients (4.3%) treated by RFA developed an ablation site
recurrence after 8 and 23 months, which were re-treated by liver resection or re-ablation, both
with curative intent. The five-year overall survival of all 106 patients undergoing simultaneous
Table 1. Clinicopathological characteristics of the patients undergoing simultaneous treatment of the primary colorectal carcinoma and liver metastases.
Total Liver resection Liver resection + RFA RFA alone P value
Number of patients 106 59 34 13
Patient characteristics
Mean age ± SD 61.3 ± 11.5 63.0 ± 11.3 58.8 ± 11.0 59.8 ± 13.4 0.210
Male gender 59 (55.7%) 33 (55.9%) 19 (55.9%) 7 (53.8%) 0.990
Comorbidities
BMI > 30 14 (13.9%) 6 (10.3%) 7 (21.9%) 1 (9.1%) 0.282
Smoking 22 (21.2%) 14 (24.1%) 5 (15.2%) 3 (23.1%) 0.591
ASA score 3 15 (15.0%) 10 (17.5%) 5 (15.6%) 0 (0%) 0.326
Cardiovascular medication 47 (44.3%) 25 (42.4%) 15 (44.1%) 7 (53.8%) 0.752
Diabetic medication 5 (4.7%) 1 (1.7%) 2 (5.9%) 2 (15.4%) 0.101
Syst. corticosteroid medication 6 (5.7%) 1 (1.7%) 5 (14.7%) 0 (0%) 0.021
Obstructive lung disease 10 (9.4%) 6 (10.2%) 3 (8.8%) 1 (8.3%) 0.952
Tumor characteristics
Rectal primary 71 (67.0%) 36 (61.0%) 24 (70.6%) 11 (84.6%) 0.226
N+ disease 66 (62.3%) 40 (67.8%) 21 (61.8%) 5 (38.5%) 0.142
Diameter CRLM in cm (median, IQR) 2.2 (1.5–3.5) 2.5 (1.5–4.0) 2.0 (1.2–3.3) 1.7 (0.9–2.7) 0.092
>1 CRLM 74 (69.8%) 34 (57.6%) 34 (100%) 6 (46.2%) <0.001
Bilobar disease 35 (33.0%) 7 (11.9%) 26 (76.5%) 2 (15.4%) <0.001
Preoperative factors
Neoadjuvant chemotherapy 69 (66.0%) 34 (57.6%) 28 (82.4%) 7 (53.8%) 0.036
Low clinical risk score (0–2) [21] 57 (53.8%) 33 (55.9%) 15 (44.1%) 9 (69.2%) 0.268
Surgery
Surgery > 8 hours 58 (55.2%) 32 (54.2%) 20 (58.8%) 6 (50.0%) 0.846
Blood loss > 500ml 49 (48.5%) 25 (45.5%) 17 (50.0%) 5 (41.7%) 0.705
Extent of liver surgery <0.001
 3 segments 28 (26.4%) 23 (39.0%) 5 (14.7%) -
1 or 2 segments 18 (17.0%) 12 (20.3%) 6 (17.6%) -
Local treatment 60 (56.6%) 24 (40.7%) 23 (67.6%) 13 (100%)
• Wedge resection 24 24 - -
• RFA 13 - - 13
• RFA + wedge resection 23 - 23 -
Type of colorectal surgery 0.460
APR 24 (22.6%) 12 (20.3%) 7 (20.6%) 5 (38.5%)
LAR 48 (44.3%) 25 (42.4%) 17 (50.0%) 6 (38.5%)
Colon 34 (33.0%) 22 (37.3%) 10 (29.4%) 2 (23.1%)
RFA = radiofrequency ablation, APR = abdominoperineal resection, LAR = low anterior resection, N+ = lymph node positive primary tumor, ASA-score = American
Society of Anaesthesiologists physical status classification system.
Cardiovascular medication includes: regulators of blood pressure and anticoagulants.
Diabetic medication includes: insulin derivatives and DM type 2 variants (e.g. metformin, tolbutamide).
Obstructive lung disease is defined as COPD and/or asthma.
https://doi.org/10.1371/journal.pone.0193385.t001
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treatment was 54.3% with a median overall survival of 70.2 months (95%CI = 43.0–97.5). S1
Table shows all complications registered and categorized in liver-related, bowel-related and
general complications stratified by type of liver treatment.
Multivariate analysis of complication rate and severity in simultaneous
treatment
In this study, we separately analyzed the complication rate and the complication severity in
patients undergoing simultaneous treatment (Tables 2 and 3). To this end we performed a
regression analysis to determine the risk factors for developing any complication (complica-
tion rate, Table 2). Secondly, we performed a regression analysis to determine the risk factors
for developing a high CCI only in the group of patients who developed complications (compli-
cation severity, Table 3). In total, 63 of 106 patients (59.4%) suffered from complications.
Table 2 shows that patients undergoing an APR (p = 0.027) and patients older than 60 years
(p = 0.022) have a higher complication rate. With respect to the treatment of the primary
tumor, patients who underwent an APR (20/24) more often suffered complications compared
to low anterior resection (LAR) (25/48; p = 0.01) or colon treatment (18/34; p = 0.016). Of
note, in univariate analysis of patients that underwent RFA, the diameter of the ablated
Table 2. Regression analysis of complication rate.
Univariable analysis Multivariable analysis
Factors P value HR 95% CI P value HR 95% CI
Patient characteristics
Female sex 0.244 0.628 0.287–1.373
Age > 60 years 0.068 2.095 0.946–4.639 0.022 3.118 1.176–8.262
BMI > 30 0.638 0.977 0.885–1.078
Current smoking 0.741 0.848 0.320–2.248
Comorbidity
ASA score 3 0.260 2.020 0.595–6.861
Cardiovascular medication 0.224 1.635 0.741–3.607
Diabetic medication 0.979 1.025 0.164–6.407
Syst. corticosteroid medication 0.248 3.621 0.408–32.140
Obstructive lung disease 0.070 7.000 0.853–57.448 0.057 8.231 0.936–73.999
Tumor characteristics
High CRS (3–5) [21] 0.728 1.148 0.527–2.502
Bilobar disease 0.615 1.238 0.539–2.845
Treatment
Neoadjuvant chemo 0.405 0.704 0.308–1.608
> 1 liver segment surgery 0.146 1.075 0.445–2.598 0.079 2.422 0.902–6.502
Major liver surgery 0.872 1.808 0.814–4.018
RFA performed 0.979 1.011 0.463–2.206
APR performed 0.010 4.535 1.425–14.433 0.027 4.382 1.180–16.277
Operation > 8 hours 0.008 2.986 1.333–6.688 0.489 1.417 0.528–3.802
Blood loss > 500ml 0.167 1.768 0.788–3.968 0.315 1.671 0.613–4.554
A binary logistic regression analysis was performed with complication rate as the dependent variable (n = 106). Variables with a p-value < 0.17 were entered in the
multivariable analysis.
RFA = radiofrequency ablation, APR = abdominoperineal resection, CRS = clinical risk score, BMI = body mass index, ASA-score = American Society of
Anaesthesiologists physical status classification system.
https://doi.org/10.1371/journal.pone.0193385.t002
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metastases was larger in patients with complications (18.6mm ± 10.5) versus those without
complications (12.8mm ± 6.4, p = 0.023).
When comparing the CCI in the patients who actually suffered from complications, uni-
variable analysis showed that RFA-treated patients had a lower complication severity
(27.9 ± 13.0) compared to non-RFA-treated patients. (39.6 ± 23.3; p = 0.021). This difference
in complication severity maintained significance in the multivariable analysis (p = 0.040;
Table 3).
Survival in matched analysis simultaneous vs. colorectal-first
To confirm the findings of previous research of comparable survival in the simultaneous ver-
sus the colorectal-first approach, we performed a matched analysis. A matched pair analysis
was performed to reduce bias due to confounding variables. Seventy patients who underwent
colorectal-first surgery were successfully matched to 70 patients (70/106; 66.0%) who under-
went simultaneous treatment. Table 4 shows the clinicopathological characteristics of matched
patients with synchronous liver metastases undergoing simultaneous versus colorectal-first
treatment. Fig 1 shows comparable survival curves in the simultaneous group and colorectal-
first group, with 5-year overall survival of 43.8% and 43.0% and median overall survival of 48.9
months (95%CI = 42.8–55.0) and 55.2 months (95%CI = 41.7–68.7), respectively (p = 0.223).
Table 3. Regression analysis of the comprehensive complication index (CCI) of patients with complications.
Univariable analysis Multivariable analysis
Factors P value P value Standardized Beta
Patient characteristics
Female sex 0.618
Age > 60 years 0.762
BMI > 30 0.239
Current smoking 0.383
Comorbidity
ASA score 3 0.259
Cardiovascular medication 0.874
Diabetic medication 0.712
Syst. corticosteroid medication 0.138 0.290 -0.134
Obstructive lung disease 0.323
Tumor characteristics




> 1 liver segment surgery 0.993
Major liver surgery 0.462
RFA performed 0.021 0.040 -0.263
APR performed 0.306
Operation > 8 hours 0.377
Blood loss > 500ml 0.421
A linear regression was performed in all patients who developed complications (n = 63), with CCI score as the dependent variable. Variables with a p-value < 0.17 were
entered in the multivariable analysis.
RFA = radiofrequency ablation, APR = abdominoperineal resection, CRS = clinical risk score, BMI = body mass index, ASA-score = American Society of
Anaesthesiologists physical status classification system.
https://doi.org/10.1371/journal.pone.0193385.t003
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Survival in matched analysis in RFA with or without liver resection vs. liver
resection alone
Thirty-five patients (35/47; 74.5%) who underwent a treatment including RFA, either as a sole
treatment or in combination with liver resection (RFA ± liver resection treatment), were suc-
cessfully matched to 35 patients in whom no RFA was applied and only underwent liver resec-
tion. Table 5 shows the clinicopathological characteristics of all matched patients. Fig 2 shows
comparable survival curves in the RFA group and the liver resection group, with 5 year overall
survival of 49.2% and 56.3% and median overall survival of 48.4 months (95%CI = 18.3–78.4)
and 70.2 months (95%CI = 31.1–109.3), respectively (p = 0.782). Likewise, Fig 3 shows compa-
rable survival curves in the RFA group and the liver resection group concerning disease-free
survival (DFS), with a 5 year DFS of 39.1% and 30.1% and a median DFS of 44.1 months (95%
CI = 29.2–59.0) and 38.4 months (95%CI = 11.7–65.1), respectively (p = 0.683).
Discussion
The main finding of this study in patients with synchronous colorectal liver metastases who
underwent simultaneous surgery of the primary tumor and its liver metastases, is that the CCI,
as a comprehensive score of all occurring complications including their weighted severity,
showed that RFA had a lower complication severity compared to liver resection only. Addi-
tionally, RFA treatment of the liver metastases—either alone or as an adjunct to liver resection-
has a comparable overall survival and disease-free survival as liver resection alone. Of note, the
surgical procedure performed for treatment of the primary tumor (APR) and a patient charac-
teristic (age > 60) were associated with a higher complication rate. To corroborate findings as
Table 4. Clinicopathological characteristics of matched patients with synchronous liver metastases undergoing simultaneous or colorectal-first treatment.
Simultaneous (n = 70) Colorectal first (n = 70) P-value
Patient characteristics
Mean age ± SD 62.2 ± 11.6 62.3 ± 9.0 0.947
Male gender 37 (52.9%) 34 (48.6%) 0.720
Extent of liver surgery 0.475
3 segments 25 (35.7%) 27 (38.6%)
1 or 2 segments 13 (18.6%) 14 (20.0%)
RFA or wedge resection 32 (45.7%) 29 (41.4%)
RFA 0.424a
RFA as part of treatment 30 (42.9%) 25 (35.7%)
• RFA + resection 19 (29.9%) 11 (15.7%)
• Only RFA 11 (15.7%) 20.0%)
Of which percutaneous 0 10 (14.3%)
Characteristics tumor
Low clinical risk score (0–2)[21] 37 (52.9%) 36 (51.4%) 1.000
Diam. CRLM in cm (median ± IQR) 2.5 ± 2.5 3.0 ± 3.5 0.106
Neoadjuvant chemotherapy 35 (50.0%) 32 (45.7%) 0.690
Primary tumor at rectal site 36 (51.4%) 34 (48.6%) 0.832
Bilobar liver disease 23 (32.9%) 32 (45.7%) 0.160
Matching was performed based on the characteristics: location of primary tumor, major/minor liver surgery, type of liver procedure, clinical risk score, sex, age and
neoadjuvant chemotherapy.
P values were calculated using the paired T test, McNemar test or Wilcoxon signed rank test.
a RFA vs. no RFA in simultaneous vs. colorectal-first treatment.
https://doi.org/10.1371/journal.pone.0193385.t004
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published by most other medical centers, we could also demonstrate in a matched analysis that
patients undergoing simultaneous surgery had a similar overall survival compared to patients
undergoing colorectal-first surgery. Of note, two out of nine centers in the review by Siriwar-
dena et al. presented a worse survival for the patients undergoing simultaneous surgery com-
pared to staged resection [24].
There is considerable variation in survival rates among studies comparing RFA with liver
resection, both for the overall and the disease free survival [13,15,25–27]. In our study,
almost half of patients undergoing simultaneous treatment were treated with RFA. Twenty-
eight out of the 47 RFA-treated patients underwent RFA because of bilobar liver metastases.
The other treatment option for bilobar CRLM is a two-stage hepatectomy, in which around
30% of the patients planned for a 2-stage hepatectomy actually never undergo the second
procedure [28–30]. In a recent study with matched patients -matching based on oncological
prognostic markers-, survival rate in a two-stage hepatectomy was compared to a one-stage
hepatectomy [31]. In the latter patient group, parenchyma-sparing, ultrasound guided liver
surgery was performed with complete tumor clearance in one procedure. The authors found
that drop out (38.1%) in the two-stage group was not caused by selection of patients with
oncological more aggressive tumors, but by the inability to obtain complete liver tumor
clearance in one procedure. In parallel, we suggest that the use of RFA to obtain complete
Fig 1. Overall survival in matched patients: Simultaneous treatment vs. colorectal-first. Comparison of patients
with synchronous CRLM undergoing the simultaneous treatment or the colorectal-first approach. P-value = 0.223
(stratified log-rank test).
https://doi.org/10.1371/journal.pone.0193385.g001
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tumor clearance in one procedure in these patients will have the best chance on intentional
curative treatment.
Progression of the CRLM has been observed after removal of the primary tumor, which
suggests that simultaneous resection of both the colorectal primary and the liver tumor might
yield better oncological outcome [32–34]. Two large multicentre studies [1,6] and our results
show that the overall survival comparing colorectal-first and simultaneous strategies is similar.
A recent study analyzed the effect of resection of the primary tumor on synchronous liver
metastases with a multivariate model to predict progressive disease, in which the only adverse
prognostic variable was undergoing an upfront primary colorectal resection [35].
In our study, the extent of liver surgery in simultaneous procedures did not substantially
contribute to the rate and severity of complications. This favorable complication pattern may
be due to selection of patients, since the combination of APR with major liver resection was
scarce. Our results of a lower complication rate in RFA patients with simultaneous treatment
is in concordance with a consensus statement on RFA treatment in general as compared to
liver resection [12]. Concerning treatment of the primary colorectal cancer, we and others
show both higher complication rates in patients undergoing APR, compared to both LAR and
colon surgery [36–38].
A limitation of this study is its retrospective design. This study, however has its merits
because it describes an observation of clinical decision-making. We realize that this study has
limited power due to the number of patients, however, this is the largest study to date analyz-
ing RFA in simultaneous resections.
In conclusion, patients who underwent RFA of liver metastases show similar oncological
outcome and lower complication severity compared to liver resection in simultaneous
Table 5. Clinicopathological characteristics of matched patients undergoing RFA as a part of treatment vs. liver resection only.
Liver resection (n = 35) RFA ± resection (n = 35) P-value
Patient characteristics
Mean age ± SD 59.6 ± 12.2 64.2 ± 10.6 0.037
Male sex 20 (57.1%) 20 (57.1%) 1.000
Extent of liver intervention 0.549 a
3 segments 6 (17.1%) 5 (14.3%)
1 or 2 segments 6 (17.1%) 6 (17.1%)
Wedge resection 23 (65.7%) 15 (42.8%)
Only RFA - 9 (25.7%)
Type of colorectal surgery 0.228
Abdominoperineal resection 8 (22.9%) 8 (22.9%)
Low anterior resection 14 (40.0%) 16 (45.7%)
Colon 13 (37.1%) 11 (31.4%)
Characteristics tumor
Low clinical risk score (0–2) [21] 20 (57.1%) 22 (62.9%) 0.774
Diam. CRLM in cm (median ± IQR) 2.2 ± 2.0 1.9 ± 1.8 0.268
Neoadjuvant chemotherapy 24 (68.6%) 25 (71.4%) 1.000
Primary tumor at rectal site 23 (65.7%) 24 (68.6%) 1.000
Bilobar disease 6 (37.1%) 23 (65.7%) <0.001
Matching was performed based on the characteristics: type of colorectal surgery, major/minor liver surgery, clinical risk score, age and neoadjuvant chemotherapy.
a McNemar test for a 3x3 comparison of ‘>3 segments’ vs. ‘1 or 2 segments’ vs. ‘wedge/RFA’.
P values were calculated using the paired T test, McNemar test or Wilcoxon signed rank test.
https://doi.org/10.1371/journal.pone.0193385.t005
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Fig 2. Overall survival in matched patients: RFA ± resection vs. only resection. Comparison of patients with
synchronous CRLM undergoing surgical treatment including RFA (RFA ± resection) or only liver resection. P-
value = 0.782 (stratified log-rank test).
https://doi.org/10.1371/journal.pone.0193385.g002
Fig 3. Disease-free survival in matched patients: RFA ± resection vs. only resection. Comparison of patients with
synchronous CRLM undergoing surgical treatment including RFA (RFA ± resection) or only liver resection. P-
value = 0.683 (stratified log-rank test).
https://doi.org/10.1371/journal.pone.0193385.g003
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treatment of both the primary colorectal carcinoma and the liver metastases. Hence, RFA is a
useful treatment option in simultaneous resections.
Supporting information
S1 Table. All complications registered. All complications registered, stratified by both treat-
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